Filtered By:
Drug: Coumadin

This page shows you your search results in order of relevance. This is page number 8.

Order by Relevance | Date

Total 3661 results found since Jan 2013.

Analysis of current clinical practice on initiation of anticoagulation in patients with acute ischemic stroke. (P4.298)
Conclusions:Physicians with a subspecialty in vascular neurology, those with more years of experience in practice, and those practicing at academic institutions tended to initiate anticoagulation later.Disclosure: Dr. Olivas has nothing to disclose. Dr. Ajani has nothing to disclose. Dr. Yao has nothing to disclose. Dr. Sangha has nothing to disclose.
Source: Neurology - April 17, 2017 Category: Neurology Authors: Olivas, E., Ajani, Z., Yao, J., Sangha, N. Tags: In-Hospital Stroke Care Source Type: research

Effectiveness of Nonvitamin K Antagonist Oral Anticoagulants and Warfarin for Preventing Further Cerebral Microbleeds in Acute Ischemic Stroke Patients with Nonvalvular Atrial Fibrillation and At Least One Microbleed: CMB-NOW Multisite Pilot Trial
Nonvitamin K antagonist oral anticoagulants (NOACs) are considered superior, or at least noninferior, to warfarin in preventing stroke or systemic embolism in patients with nonvalvular atrial fibrillation. Here, we recruited acute ischemic stroke patients with nonvalvular atrial fibrillation and at least one cerebral microbleed (CMB), and evaluated the proportion of patients who had an increased number of CMBs (%) after receiving anticoagulant therapy with NOACs or with warfarin for 12 months.
Source: Journal of Stroke and Cerebrovascular Diseases - April 17, 2019 Category: Neurology Authors: Mutsumi Yokoyama, Atsushi Mizuma, Tohru Terao, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Shigeru Nogawa, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, Shunya Takizawa, for the CMB-NOW Study Inves Source Type: research

Multicenter prospective analysis of stroke patients taking oral anticoagulants: The PASTA registry - Study design and characteristics
The management of atrial fibrillation and deep venous thrombosis has evolved with the development of direct oral anticoagulants (DOAC), and oral anticoagulant (OAC) might influence the development or clinical course in both ischemic and hemorrhagic stroke. However, detailed data on the differences between the effects of the prior prescription of warfarin and DOAC on the clinical characteristics, neuroradiologic findings, and outcome of stroke are limited.
Source: Journal of Stroke and Cerebrovascular Diseases - October 28, 2019 Category: Neurology Authors: Satoshi Suda, Yasuyuki Iguchi, Shigeru Fujimoto, Yoshiki Yagita, Yu Kono, Masayuki Ueda, Kenichi Todo, Tomoyuki Kono, Takayuki Mizunari, Mineo Yamazaki, Takao Kanzawa, Seiji Okubo, Kimito Kondo, Nobuhito Nakajima, Takeshi Inoue, Takeshi Iwanaga, Makoto Na Source Type: research

New anti-stroke drug available on NHS
A 'new generation' drug that dramatically cuts the risk of stroke for people with a common type of heart palpitation has been given the green light for prescription on the NHS.
Source: Telegraph Health - January 23, 2013 Category: Consumer Health News Tags: atrial fibrillation apixaban stroke AF warfarin Source Type: news

Simple Home Test Can Halve The Risk Of Stroke And Cut The Risk Of Death For Thousands Of Patients On Warfarin Therapy
MPs, clinicians and patients are uniting to drive change for patients on long-term warfarin A simple self-monitoring test could reduce the risk of stroke by half in thousands of people who currently take warfarin to prevent blood clots...
Source: Health News from Medical News Today - February 12, 2013 Category: Consumer Health News Tags: Stroke Source Type: news

Abstract 10: Contraindications to Oral Anticoagulation in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Concurrent I Session B: Oral Abstract Presentations on Stroke Topics
Conclusions. Contraindications to OAC therapy among AF patients are common and often due to high bleeding risk. Furthermore, many patients with reported contraindications are taking warfarin, suggesting that many contraindications to warfarin therapy are minor, relative, or temporary.
Source: Circulation: Cardiovascular Quality and Outcomes - May 15, 2013 Category: Cardiology Authors: O'Brien, E. C., Holmes, D., Koller, C. R., Singer, D. E., Ansell, J., Allen, L. A., Hylek, E. M., Kowey, P., Gersh, B., Fonarow, G. C., Mahaffey, K. W., Chang, P., Ezekowitz, M. D., Peterson, E. D., Piccini, J. P. Tags: Concurrent I Session B: Oral Abstract Presentations on Stroke Topics Source Type: research

Antithrombotic Drug Uses and Deep Intracerebral Hemorrhages in Stroke Patients With Deep Cerebral Microbleeds
Conclusions: Multivariate analysis revealed that the use of antiplatelet drugs or warfarin did not significantly influence the occurrence of deep ICH in patients with deep MBs. Antiplatelet drugs or warfarin did not significantly elevate the rate of deep ICHs in stroke patients with pre-existing deep MBs.
Source: Journal of Stroke and Cerebrovascular Diseases - September 10, 2012 Category: Neurology Authors: Toshio Imaizumi, Shigeru Inamura, Ikuhide Kohama, Kazuhisa Yoshifuji, Tatsufumi Nomura, Katsuya Komatsu Tags: Original Articles Source Type: research

Incidence, outcome and future projections of atrial fibrillation-related stroke and systemic embolism at age >=80 years: 10-year results of a population-based study
Conclusion Numbers of AF–related ischaemic strokes at age ≥80 years are projected to treble by 2050, along with numbers of systemic emboli, unless rates of anticoagulation in older patients increase.
Source: Journal of Neurology, Neurosurgery and Psychiatry - October 9, 2013 Category: Neurosurgery Authors: Yiin, G. S., Howard, D. P., Paul, N. L., Mehta, Z., Rothwell, P. M. Tags: Stroke Association of British Neurologists (ABN) joint meeting with the Royal College of Physicians (RCP), London, 23-24 October 2013 Source Type: research

Clopidogrel Plus Aspirin Versus Warfarin in Patients With Stroke and Aortic Arch Plaques Major Clinical Trial
Conclusions— Because of lack of power, this trial was inconclusive and results should be taken as hypothesis generating. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00235248.
Source: Stroke - April 28, 2014 Category: Neurology Authors: Amarenco, P., Davis, S., Jones, E. F., Cohen, A. A., Heiss, W.-D., Kaste, M., Laouenan, C., Young, D., Macleod, M., Donnan, G. A., The Aortic Arch Related Cerebral Hazard Trial Investigators, Bladin, Chambers, Frayne, Hankey, Levi, Read, Ravaud, Tatlisuma Tags: Anticoagulants, Antiplatelets Major Clinical Trial Source Type: research

Lateral Medullary Stroke in Patient with Granulomatous Polyangiitis
We report a 41-year-old man with lateral medullary infarction who developed rapidly progressive renal failure. He was diagnosed with GPA based on positive serum c-ANCA and antiproteinase 3 antibodies and demonstration of pauci-immune crescentic glomerulonephritis on kidney biopsy. He was treated with Coumadin, pulse steroids, cyclophosphamide, and plasmapheresis. He had resolution of his neurologic deficits and improvement in renal function. This case report highlights the importance to consider GPA vasculitis in the differential diagnosis of stroke in patients with development of acute kidney injury.
Source: Journal of Stroke and Cerebrovascular Diseases - October 14, 2013 Category: Neurology Authors: Olga D. Taraschenko, Colum F. Amory, Jonathan Waldman, Era K. Hanspal, Gary L. Bernardini Tags: Case Reports Source Type: research

Can Early Effective Anticoagulation Prevent New Lesions on Magnetic Resonance Imaging in Acute Cardioembolic Stroke?
Background: The timing of warfarin administration for acute ischemic stroke (AIS) patients with atrial fibrillation (Af) has not been established. We hypothesized that achieving targeted prothrombin time and international normalized ratio (PT-INR) at 2 weeks could prevent AIS patients with Af from developing a new lesion on diffusion-weighted magnetic resonance imaging (DW-MRI).Methods: Of consecutively enrolled AIS patients with Af between 2008 and 2011, we selected the patients who were given warfarin within 2 weeks of admission and had DW-MRI and blood test for PT-INR both on admission and at 2 weeks. Warfarin was st...
Source: Journal of Stroke and Cerebrovascular Diseases - August 8, 2014 Category: Neurology Authors: Eiichi Nomura, Tomohiko Ohshita, Eiji Imamura, Shinichi Wakabayashi, Hiroshi Kajikawa, Masayasu Matsumoto Tags: Original Articles Source Type: research

Non-vitamin-K oral anticoagulants reduce mortality, stroke and intracranial haemorrhage when compared with warfarin in randomised trials of patients with non-valvular atrial fibrillation
Commentary on: Ruff CT, Giugliano RP, Braunwald E, et al.. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014;383:955–62. Context Historically, the standard medication for stroke prevention in atrial fibrillation (AF) has been a vitamin-K antagonist (warfarin). However, several non-vitamin-K oral anticoagulants (NOACs) have been developed and shown to be at least as effective as dose-adjusted warfarin in their respective phase-3 clinical trials.1–4 These include the direct thrombin inhibitor dabig...
Source: Evidence-Based Medicine - September 15, 2014 Category: Internal Medicine Authors: Steinberg, B. A. Tags: Epidemiologic studies, Drugs: cardiovascular system, Stroke, Ischaemic heart disease, Connective tissue disease, Musculoskeletal syndromes, Diabetes, Arrhythmias Therapeutics Source Type: research

Prehospital Reversal of Warfarin-Related Coagulopathy in Intracerebral Hemorrhage in a Mobile Stroke Treatment Unit Clinical and Research Innovations
Source: Stroke - April 27, 2015 Category: Neurology Authors: Gomes, J. A., Ahrens, C. L., Hussain, M. S., Winners, S., Rasmussen, P. A., Uchino, K., on behalf of the Cleveland Pre-Hospital Acute Stroke Treatment Study Group Tags: Coumarins, Anticoagulants Clinical and Research Innovations Source Type: research

Protocol for Cerebral Microbleeds During the Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin Therapy in Stroke Patients With Nonvalvular Atrial Fibrillation (CMB-NOW) Study: Multisite Pilot Trial
Anticoagulants are widely used to prevent recurrence of ischemic stroke in patients with nonvalvular atrial fibrillation, but in some patients, they also cause bleeding, particularly intracranial hemorrhage. One of the independent predictors of intracerebral hemorrhage is the presence of cerebral microbleeds (CMBs); a high incidence of intracerebral hemorrhage is reported in warfarin-treated patients with multiple CMBs. Longitudinal study suggested that the presence of CMBs at baseline is a predictor of new CMBs in warfarin-treated patients.
Source: Journal of Stroke and Cerebrovascular Diseases - July 4, 2015 Category: Neurology Authors: Shunya Takizawa, Fumiaki Tanaka, Kazutoshi Nishiyama, Yasuhiro Hasegawa, Eiichiro Nagata, Atsushi Mizuma, Sachiko Yutani, Taira Nakayama, Hiroyuki Kobayashi, Noriharu Yanagimachi, Takashi Okazaki, Kazuo Kitagawa, CMB-NOW Study Investigators Source Type: research

Secondary Prevention of Stroke with Warfarin in Patients with Nonvalvular Atrial Fibrillation: Subanalysis of the J-RHYTHM Registry
Prior ischemic stroke or transient ischemic attack (TIA) is a high risk for thromboembolism in patients with nonvalvular atrial fibrillation (NVAF). To clarify rates of thromboembolic and hemorrhagic events, and target intensities of warfarin for secondary prevention, a subanalysis was performed using data from the J-RHYTHM Registry.
Source: Journal of Stroke and Cerebrovascular Diseases - December 22, 2015 Category: Neurology Authors: Eitaro Kodani, Hirotsugu Atarashi, Hiroshi Inoue, Ken Okumura, Takeshi Yamashita, Hideki Origasa, J-RHYTHM Registry Investigators Source Type: research